RxDoctor Payments Data

John McClanahan, DO

Family Medicine · Floydada, TXNPI 1275866212

Payments from drug & device makers

$7,864in general payments, 2019–2025

Across 501 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$674
  • Novo Nordisk$518
  • Pfizer$450
  • Astellas Pharma US Inc$380
  • Exact Sciences$377
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$7,864100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,864 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$164,781
Medicare patients
239
Services billed
3,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide113$143,502
RybelsusSemaglutide57$67,662
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$65,123
MounjaroTirzepatide56$64,004
JardianceEmpagliflozin57$57,770
FarxigaDapagliflozin Propanediol52$44,184
MyrbetriqMirabegron31$28,047
EliquisApixaban20$25,773
JanuviaSitagliptin Phosphate25$24,228
XareltoRivaroxaban14$19,570
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$11,517
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$11,288
Breo ElliptaFluticasone/Vilanterol17$7,598
LivaloPitavastatin Calcium15$5,528
BelsomraSuvorexant11$5,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$518$211,163170 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$674$84,238100 claims
Lilly USA, LLCMounjaro$273$64,00456 claims
Boehringer IngelheimJardiance$299$57,77057 claims
AstraZenecaFarxiga, Breztri Aerosphere$255$55,47266 claims
MerckJanuvia, Belsomra$327$29,23636 claims
Astellas Pharma US IncMyrbetriq$380$28,04731 claims
PfizerEliquis$450$25,77320 claims
Johnson & JohnsonXarelto$44$19,57014 claims
Kowa Pharmaceuticals America, Inc.Livalo$99$5,52815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Floydada

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →